FDA spurns J&J's troubled rheumatoid arthritis drug sirukumab
J&J $JNJ played this one straight out to the end, but after an overwhelmingly negative expert panel vote against an approval of its troubled rheumatoid arthritis drug sirukumab, the FDA has formally rejected the marketing application — ominously demanding more data for review.
J&J said after the market closed Friday that it will study the situation on this drug, which some analysts once counted as a likely blockbuster-to-be.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.